Nuvation Bio Inc. (NUVB) SEC Filings & Earnings Calls

Clinical trial failure risk for safusidenib; pipeline concentration.

“Safusidenib still in Phase 2; no guarantee of regulatory approval.”

Competitive pressure from other ROS1 TKIs.

“IBTROZI faces competition from other approved ROS1 inhibitors.”

Accumulated deficit and ongoing losses

“As of June 30, 2026, the Company has an accumulated deficit of approximately $1,172.8 million and net cash used in operating activities was approximately $37.9 million for the six months ended June 30, 2026.” · word for word

Customer concentration

“Customer A, B, and C represented 22%, 20%, and 19% of gross revenue for the three months ended June 30, 2026, respectively.”

Convertible debt and financing obligations

“Convertible debt, net of deferred financing costs of $7,376, $242,624,000 as of June 30, 2026.” · word for word

Potential dilution from convertible notes, partially offset by capped calls.

“The capped call transactions are expected generally to reduce the potential dilution to the Class A common stock upon any conversion of the Notes.”

Potential dilution from conversion of notes.

“The conversion rate for the Notes will initially be 127.4941 shares of Class A common stock per $1,000 principal amount of Notes.”

Dependence on single product IBTROZI for near-term revenue; pipeline still early-stage.

“Revenue entirely from IBTROZI; safusidenib in Phase 3; DDC platform preclinical.”

Competition in ROS1+ NSCLC market from other targeted therapies.

“Market includes entrectinib, crizotinib, and other ROS1 inhibitors.”

Customer Concentration

“Customer A 64.4% (of gross revenue for Q1 2026)”

Accumulated Deficit

“accumulated deficit of approximately $1,110.0 million”

R&D Expense Growth

“Research and development $35,047 (Q1 2026) vs $24,601 (Q1 2025), +42.4%”

Pre-commercial stage; no significant revenue

“The Company had no significant revenue during the periods presented.” · word for word

Net loss and negative TSR over three years

“Net Income (loss) ... ($ 204,627,000) ... ($ 567,939,000) ... ($ 75,802,000)”

Dependence on Single Source for Taletrectinib API

“We currently rely upon a single source for taletrectinib API and are working to develop a second source.” · word for word

Commercialization Risk for IBTROZI

“We have limited experience as a commercial company and our sales, marketing, and distribution of IBTROZI may be unsuccessful or less successful than anticipated.” · word for word

Concentrated Voting Control by CEO

“The dual-class structure of our Common Stock has the effect of concentrating voting power with our Chief Executive Officer, which limits other stockholders’ ability to influence the outcome of important transactions, including a change in control.” · word for word

Substantial Indebtedness and Debt Service Obligations

“Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.” · word for word

Dependence on IBTROZI for revenue; pipeline risk for safusidenib.

“Only source of product revenue is IBTROZI; safusidenib still in clinical trials.”

Competitive landscape in ROS1+ NSCLC.

“Other ROS1 TKIs available; IBTROZI must maintain differentiation.”

Dependence on Eisai for ex-US commercialization; potential delays in regulatory approvals.

“Eisai may terminate if regulatory approvals not obtained by certain date.”

Upfront payment may not fully offset development costs.

“Eisai obligations include development costs; company retains US rights.”

Clinical trial failure for NUV-1511; DDC platform risk.

“Lack of sufficiently consistent efficacy across cohorts led to discontinuation.” · word for word

Pipeline concentration on IBTROZI and safusidenib.

“Resources redirected to other pipeline molecules and next-generation DDC candidates.”

GCP noncompliance issue identified; resolved but may raise regulatory scrutiny.

“GCP noncompliance issue regarding collection of adverse events was identified during the study.”

Clinical trial risk for safusidenib; Phase 3 may not replicate Phase 2 results.

“Phase 2 data positive but Phase 3 still ongoing.”

Operating losses and negative cash flow

“Management expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future.” · word for word

Dependence on IBTROZI commercial success

“The Company's research and development can be costly, and the timing and outcomes are uncertain.” · word for word

Concentration of customers

“Below customers represent more than 10% of the Company's net revenue for the three and nine months ended September 30, 2025 and 2024.”

Commercial execution risk: early launch phase with limited revenue history.

“First full quarter of commercial sales; revenue of $7.7M is modest relative to cash burn.”

Clinical trial risk: pipeline dependency on safusidenib and NUV-1511 with no approved products beyond IBTROZI.

“Safusidenib in early-stage pivotal study; NUV-1511 Phase 1/2 update expected by year end.”

Regulatory risk: sNDA for IBTROZI label update and Japan reimbursement milestone pending.

“Plans to prepare sNDA; $25M milestone contingent on Japan reimbursement price establishment.”